Abstract
Cancer immunotherapy has emerged as a promising treatment strategy, leveraging the body's immune system to fight cancer. The integration of big data, including genomic, transcriptomic, proteomic, and clinical data, has revolutionized cancer immunotherapy research by providing deeper insights into tumor biology, immune response, and treatment outcomes. This article explores the role of big data in cancer immunotherapy, focusing on how it enables the identification of new therapeutic targets, the prediction of patient responses, and the optimization of treatment strategies. We also discuss the challenges and future directions of big data integration in cancer immunotherapy research.
All articles published in the American Journal of Bioinformatics (AJB) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license, authors retain full copyright of their work and grant permission to anyone to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Conditions:
-
Attribution: Appropriate credit must be given to the original author(s) and the source, a link to the license must be provided, and any changes made must be indicated.
-
No additional restrictions: You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This open-access license ensures that scholarly work published in AJB is freely accessible and usable, promoting knowledge dissemination and academic collaboration worldw